Eli Lilly delivered exceptional Q2 2024 results, with revenue growth of 36% driven by strong performance of new products, particularly Mounjaro and Zepbound.
Top Takeaways
- Revenue grew 36% in Q2, with new products contributing nearly $3.5 billion in growth compared to the same period last year.
- Mounjaro and Zepbound sales exceeded expectations, with combined U.S. sales of $3.6 billion in Q2.
- Lilly raised full-year revenue guidance by $3 billion, reflecting strong performance and increased confidence in production expansion.
- The company received FDA approval for Kisunla (donanemab) for Alzheimer’s disease treatment.
- Lilly is investing heavily in manufacturing expansion, committing over $18 billion since 2020 to build, upgrade, or acquire facilities in the U.S. and Europe.
Summary
Eli Lilly’s Q2 2024 performance was marked by accelerated growth, with revenue increasing 36% to $45.4-$46.6 billion. The company’s new products, particularly Mounjaro and Zepbound, drove this exceptional growth. CEO Dave Ricks highlighted the company’s progress:
“It’s an exciting time here at Lilly as our growth trajectory accelerated in the second quarter. Our investments in advancing innovative medicine are focused on manufacturing expansion are bringing Lilly medicines to more people around the world.”
Main Themes
- Guidance: Full-year revenue outlook raised by $3 billion to $45.4-$46.6 billion
- New Product Announcements: FDA approval of Kisunla for Alzheimer’s disease treatment
- Manufacturing Expansion: $18 billion committed since 2020 for facility upgrades and acquisitions
- Pipeline Progress: Positive Phase 3 results for tirzepatide in heart failure and obesity
- Market Opportunity: Expanding presence in obesity and diabetes markets globally
Insights
Lilly’s strategy in the obesity market is comprehensive, addressing multiple mechanisms, indications, and dosage forms. The company now has 11 new molecules in clinical trials across various indications, demonstrating its commitment to this growing market segment.
Market Opportunity
Lilly is targeting the global obesity market, which represents a significant growth opportunity. The company is expanding its presence in international markets, with Mounjaro launches progressing well in countries like the UK, Germany, and UAE. The addressable market for obesity treatments is expanding as more employers opt into coverage for these medications.
Market Commentary
The obesity treatment market is experiencing rapid growth and increased competition. Lilly is positioning itself as a leader in this space through its comprehensive approach to drug development and manufacturing expansion. The company’s focus on multiple mechanisms and formulations (oral and injectable) aims to address various patient needs and preferences.
Customer Behaviors
Patient demand for Mounjaro and Zepbound remains strong and growing. Lilly is working to improve patient persistence with therapy by enhancing consumer platforms and digital channels. The company is also engaging with employers to communicate the broader health and productivity benefits of obesity treatments.
Capex
Lilly announced an additional $5.3 billion investment in its Lebanon, Indiana manufacturing site, bringing the total investment there to $9 billion. This expansion will enhance capacity to manufacture active pharmaceutical ingredients for Zepbound and Mounjaro.
Regulatory Policy
Lilly received FDA approval for Kisunla (donanemab) for Alzheimer’s disease treatment. The approval includes labeling that allows physicians to consider stopping dosing based on reduction of amyloid plaques, potentially leading to lower treatment costs and fewer infusions required.
Economy Insights
While specific economic commentary was limited, Lilly’s strong performance and increased guidance suggest resilient demand for its products despite broader economic uncertainties.
Industry Insights
Lilly’s success in the obesity and diabetes markets may have positive implications for other players in the pharmaceutical industry focused on these therapeutic areas. The company’s manufacturing expansion efforts highlight the importance of robust supply chains in meeting growing demand for innovative treatments.
Key Metrics
Financial Metrics
- Revenue growth: 36% YoY
- U.S. revenue growth: 42% YoY
- Operating income increase: 90% YoY
- Earnings per share: $3.92, up 86% YoY
KPIs
- Mounjaro global sales: $3.1 billion
- Zepbound U.S. sales: Over $1.2 billion
- Verzenio sales growth: 44% YoY
- Commercial access for Zepbound: 86% as of July 1
Competitive Differentiators
- Comprehensive obesity treatment portfolio with 11 molecules in clinical trials
- Strong manufacturing capabilities and ongoing expansion efforts
- Multiple formulations (oral and injectable) addressing various patient needs
- Robust pipeline across multiple therapeutic areas
- Successful launch and rapid uptake of new products like Mounjaro and Zepbound
Key Risks
- Potential supply constraints due to high demand for incretin medicines
- Increasing competition in the obesity and diabetes markets
- Regulatory challenges and potential pricing pressures
- Dependence on key products for growth
- Manufacturing and supply chain complexities
Analyst Q&A Focus Areas
Analysts focused on:
- Pricing dynamics and average selling prices for incretin medicines
- Manufacturing capacity and supply chain challenges
- Differentiation strategies for oral obesity treatments
- Ex-U.S. market opportunities and reimbursement landscape
- Potential for muscle-preserving obesity drugs
Eli Lilly Summary:
Eli Lilly’s exceptional Q2 2024 performance demonstrates the company’s strong position in the rapidly growing obesity and diabetes markets. With significant investments in manufacturing capacity, a robust pipeline, and successful new product launches, Lilly is well-positioned for continued growth. Investors should watch for further developments in the company’s obesity treatment portfolio, international market expansions, and progress in addressing supply chain challenges to meet the growing demand for its innovative medicines.
